{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:23:34Z","timestamp":1792113814466,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40265-024-02134-0","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T06:39:48Z","timestamp":1738823988000},"page":"415-423","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Rezafungin: A Review in Invasive Candidiasis"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0789-7765","authenticated-orcid":false,"given":"Simon","family":"Fung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Shirley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"issue":"9","key":"2134_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1080\/14787210.2023.2240956","volume":"21","author":"A Oliva","year":"2023","unstructured":"Oliva A, De Rosa FG, Mikulska M, et al. Invasive Candida infection: epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin. Expert Rev Anti Infect Ther. 2023;21(9):957\u201375.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"10","key":"2134_CR2","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.cmi.2019.04.024","volume":"25","author":"P Koehler","year":"2019","unstructured":"Koehler P, Stecher M, Cornely OA, et al. Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. Clin Microbiol Infect. 2019;25(10):1200\u201312.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"2134_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13054-019-2497-3","volume":"23","author":"M Bassetti","year":"2019","unstructured":"Bassetti M, Giacobbe DR, Vena A, et al. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Crit Care. 2019;23(1):219.","journal-title":"Crit Care"},{"issue":"9","key":"2134_CR4","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00134-015-3866-2","volume":"41","author":"M Bassetti","year":"2015","unstructured":"Bassetti M, Righi E, Ansaldi F, et al. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med. 2015;41(9):1601\u201310.","journal-title":"Intensive Care Med"},{"issue":"6","key":"2134_CR5","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S1473-3099(22)00872-6","volume":"23","author":"M Hoenigl","year":"2023","unstructured":"Hoenigl M, Salmanton-Garcia J, Egger M, et al. Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study. Lancet Infect Dis. 2023;23(6):751\u201361.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"2134_CR6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-50.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 7","key":"2134_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1469-0691.12039","volume":"18","author":"OA Cornely","year":"2012","unstructured":"Cornely OA, Bassetti M, Calandra T, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18(Suppl 7):19\u201337.","journal-title":"Clin Microbiol Infect"},{"issue":"24","key":"2134_CR8","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1056\/NEJMoa066906","volume":"356","author":"AC Reboli","year":"2007","unstructured":"Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356(24):2472\u201382.","journal-title":"N Engl J Med"},{"issue":"2","key":"2134_CR9","doi-asserted-by":"publisher","first-page":"e01541","DOI":"10.1128\/AAC.01541-16","volume":"61","author":"KD James","year":"2017","unstructured":"James KD, Laudeman CP, Malkar NB, et al. Structure-activity relationships of a series of echinocandins and the discovery of CD101, a highly stable and soluble echinocandin with distinctive pharmacokinetic properties. Antimicrob Agents Chemother. 2017;61(2):e01541-e1616.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"2134_CR10","doi-asserted-by":"publisher","first-page":"e00758","DOI":"10.1128\/AAC.00758-17","volume":"61","author":"EA Lakota","year":"2017","unstructured":"Lakota EA, Bader JC, Ong V, et al. Pharmacological basis of CD101 efficacy: exposure shape matters. Antimicrob Agents Chemother. 2017;61(11):e00758-817.","journal-title":"Antimicrob Agents Chemother"},{"key":"2134_CR11","unstructured":"European Medicines Agency. Rezzayo: EU summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/. Accessed 26 Nov 2024."},{"key":"2134_CR12","unstructured":"Medicines & Healthcare products Regulatory Agency. REZZAYO 200 mg powder for concentrate for solution for infusion: UK summary of product characteristics. 2024. https:\/\/products.mhra.gov.uk\/. Accessed 26 Nov 2024."},{"key":"2134_CR13","unstructured":"US Food and Drug Administration. FDA letter of NDA approval for rezafungin. 2023. https:\/\/www.fda.gov\/. Accessed 26 Nov 2024."},{"key":"2134_CR14","unstructured":"EUCAST: European Committee on Antimicrobial Susceptibility Testing. Rezafungin: rationale for the clinical breakpoints, version 1.0 2023. 2024. http:\/\/www.eucast.org. Accessed 26 Nov 2024."},{"issue":"4","key":"2134_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/jcm.02449-21","volume":"60","author":"CG Carvalhaes","year":"2022","unstructured":"Carvalhaes CG, Klauer AL, Rhomberg PR, et al. Evaluation of rezafungin provisional CLSI clinical breakpoints and epidemiological cutoff values tested against a worldwide collection of contemporaneous invasive fungal isolates (2019 to 2020). J Clin Microbiol. 2022;60(4):1\u201311.","journal-title":"J Clin Microbiol"},{"key":"2134_CR16","unstructured":"CLSI. Performance standards for antifungal susceptibility testing of yeasts. CLSI document M27M44S. 3rd ed. Procop GW, editor. Wayne, PA: Clinical and Laboratory Standards Institute; 2022."},{"issue":"10","key":"2134_CR17","doi-asserted-by":"publisher","first-page":"6100","DOI":"10.1128\/AAC.00620-16","volume":"60","author":"JB Locke","year":"2016","unstructured":"Locke JB, Almaguer AL, Zuill DE, et al. Characterization of in vitro resistance development to the novel echinocandin CD101 in Candida species. Antimicrob Agents Chemother. 2016;60(10):6100\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2134_CR18","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/jac\/dkad055","volume":"78","author":"DE Zuill","year":"2023","unstructured":"Zuill DE, Almaguer AL, Donatelli J, et al. Development and preliminary validation of a modified EUCAST yeast broth microdilution MIC method with Tween 20-supplemented medium for rezafungin. J Antimicrob Chemother. 2023;78(4):1102\u201310.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"2134_CR19","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1093\/jac\/dky153","volume":"73","author":"CL Hager","year":"2018","unstructured":"Hager CL, Larkin EL, Long LA, et al. Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model. J Antimicrob Chemother. 2018;73(8):2085\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"2134_CR20","doi-asserted-by":"publisher","first-page":"e01572","DOI":"10.1128\/AAC.01572-18","volume":"62","author":"AJ Lepak","year":"2018","unstructured":"Lepak AJ, Zhao M, Andes DR. Pharmacodynamic evaluation of rezafungin (CD101) against Candida auris in the neutropenic mouse invasive candidiasis model. Antimicrob Agents Chemother. 2018;62(11):e01572-e1618.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"2134_CR21","doi-asserted-by":"publisher","first-page":"e01556","DOI":"10.1128\/AAC.01556-19","volume":"63","author":"AJ Lepak","year":"2019","unstructured":"Lepak AJ, Zhao M, Andes DR. Determination of pharmacodynamic target exposures for rezafungin against Candida tropicalis and Candida dubliniensis in the neutropenic mouse disseminated candidiasis model. Antimicrob Agents Chemother. 2019;63(11):e01556-e1619.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2134_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/aac.00916-23","volume":"67","author":"S Roepcke","year":"2023","unstructured":"Roepcke S, Passarell J, Walker H, et al. Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis. Antimicrob Agents Chemother. 2023;67(12):1\u201316.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2134_CR23","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/phar.2943","volume":"44","author":"S Flanagan","year":"2024","unstructured":"Flanagan S, Ong V, Marbury T, et al. Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate\/severe hepatic impairment and matched control subjects. Pharmacotherapy. 2024;44(6):435\u201343.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"2134_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/spectrum.01339-23","volume":"11","author":"S Flanagan","year":"2023","unstructured":"Flanagan S, Walker H, Ong V, et al. Absence of clinically meaningful drug-drug interactions with rezafungin: outcome of investigations. Microbiol Spectr. 2023;11(3):1\u201314.","journal-title":"Microbiol Spectr."},{"issue":"2","key":"2134_CR25","doi-asserted-by":"publisher","first-page":"e01627","DOI":"10.1128\/AAC.01627-16","volume":"61","author":"T Sandison","year":"2017","unstructured":"Sandison T, Ong V, Lee J, et al. Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults. Antimicrob Agents Chemother. 2017;61(2):e01627-e1716.","journal-title":"Antimicrob Agents Chemother"},{"key":"2134_CR26","unstructured":"US Food and Drug Administration. REZZAYO\u2122 (rezafungin for injection), for intravenous use: US prescribing information. 2023. https:\/\/www.fda.gov\/. Accessed 26 Nov 2024."},{"issue":"11","key":"2134_CR27","doi-asserted-by":"publisher","first-page":"6872","DOI":"10.1128\/AAC.00701-16","volume":"60","author":"V Ong","year":"2016","unstructured":"Ong V, Hough G, Schlosser M, et al. Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin. Antimicrob Agents Chemother. 2016;60(11):6872\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2134_CR28","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/s13054-024-05117-5","volume":"28","author":"P Honor\u00e9","year":"2024","unstructured":"Honor\u00e9 P, Girardis M, Kollef M, et al. Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials. Crit Care. 2024;28(1):348.","journal-title":"Crit Care"},{"issue":"11","key":"2134_CR29","doi-asserted-by":"publisher","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","volume":"73","author":"GR Thompson 3rd","year":"2021","unstructured":"Thompson GR 3rd, Soriano A, Skoutelis A, et al. Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial. Clin Infect Dis. 2021;73(11):e3647\u201355.","journal-title":"Clin Infect Dis"},{"issue":"10370","key":"2134_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","volume":"401","author":"GR Thompson 3rd","year":"2023","unstructured":"Thompson GR 3rd, Soriano A, Cornely OA, et al. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet. 2023;401(10370):49\u201359.","journal-title":"Lancet"},{"issue":"10","key":"2134_CR31","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","volume":"13","author":"WA Knaus","year":"1985","unstructured":"Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818\u201329.","journal-title":"Crit Care Med"},{"issue":"5","key":"2134_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/aac.01584-23","volume":"68","author":"JB Locke","year":"2024","unstructured":"Locke JB, Pillar CM, Castanheira M, et al. Outcomes by Candida spp. in the ReSTORE phase 3 trial of rezafungin versus caspofungin for candidemia and\/or invasive candidiasis. Antimicrob Agents Chemother. 2024;68(5):1\u201311.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"2134_CR33","first-page":"adad06632","volume":"5","author":"T Sandison","year":"2023","unstructured":"Sandison T, Ramos-Martinez A, Kim YK, et al. Rezafungin efficacy and safety in immunocompromised patients: sub-analyses of the Phase 3 trial in treatment of candidaemia and invasive candidiasis [abstract no. P28]. JAC Antimicrob Resist. 2023;5(Suppl 2):adad06632.","journal-title":"JAC Antimicrob Resist."},{"issue":"3","key":"2134_CR34","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S1473-3099(23)00551-0","volume":"24","author":"GR Thompson 3rd","year":"2023","unstructured":"Thompson GR 3rd, Soriano A, Honore PM, et al. Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials. Lancet Infect Dis. 2023;24(3):319\u201328.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2134_CR35","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s13054-024-05152-2","volume":"28","author":"PM Honore","year":"2024","unstructured":"Honore PM, Bassetti M, Cornely OA, et al. Length of hospital and intensive care unit stay in patients with invasive candidiasis and\/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials. Crit Care. 2024;28(1):361.","journal-title":"Crit Care"},{"key":"2134_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.891336","volume":"13","author":"ZX Zhou","year":"2022","unstructured":"Zhou ZX, Yin XD, Zhang Y, et al. Antifungal drugs and drug-induced liver injury: a real-world study leveraging the FDA adverse event reporting system database. Front Pharmacol. 2022;13: 891336.","journal-title":"Front Pharmacol"},{"key":"2134_CR37","unstructured":"Cornely OA, Sprute R, Bassetti M, et al. Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM [draft]. 2024."},{"key":"2134_CR38","unstructured":"Castanheira M, Rhomberg P, Deshpande L, et al. Rezafungin activity against echinocandin, nonwildtype Candida glabrata clinical isolates collected in European countries (2014\u20132021) [abstract no. E0542]. In: 34th Congress of the European Society of Clinical Microbiology and Infectious Diseases. 2024."},{"issue":"Suppl. 2","key":"2134_CR39","first-page":"S324","volume":"9","author":"CM Rubino","year":"2022","unstructured":"Rubino CM, Flanagan S, Locke JB. Impact of elevated MIC values on echinocandin pharmacokinetic-pharmacodynamic (PK-PD) Candida glabrata target attainment (TA) [abstract no. 592]. Open Forum Infect Dis. 2022;9(Suppl. 2):S324\u20135.","journal-title":"Open Forum Infect Dis"},{"key":"2134_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae415","author":"D Andes","year":"2024","unstructured":"Andes D, Bruggemann RJ, Flanagan S, et al. The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics. J Antimicrob Chemother. 2024. https:\/\/doi.org\/10.1093\/jac\/dkae415.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2134_CR41","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4103\/2229-5151.164940","volume":"5","author":"C Kornbau","year":"2015","unstructured":"Kornbau C, Lee KC, Hughes GD, et al. Central line complications. Int J Crit Illn Inj Sci. 2015;5(3):170\u20138.","journal-title":"Int J Crit Illn Inj Sci"},{"issue":"1","key":"2134_CR42","doi-asserted-by":"publisher","first-page":"ofad703","DOI":"10.1093\/ofid\/ofad703","volume":"11","author":"TP Lodise","year":"2024","unstructured":"Lodise TP, Garey KW, Aram JA, et al. Healthcare resource utilization and discharge readiness in adult hospitalized patients with candidemia or invasive candidiasis who received an echinocandin: an analysis of united states hospitals. Open Forum Infect Dis. 2024;11(1):ofad703.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"2134_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jacamr\/dlad079","volume":"5","author":"J Jeck","year":"2023","unstructured":"Jeck J, Jakobs F, Kurte MS, et al. Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis. JAC Antimicrob Resist. 2023;5(3):1\u20137.","journal-title":"JAC Antimicrob Resist."},{"key":"2134_CR44","unstructured":"Chiurlo M, Placella G, Badalucco Ciotta F, et al. First case of Candida glabrata prosthetic knee infection treated with rezafungin: case report [abstract no. P3398]. In: 33rd ECCMID 2023, 15\u201318 April 2023. 2023."},{"key":"2134_CR45","unstructured":"Trapani F, Pascale R, Amedeo A, et al. Successful treatment of Candida endocarditis with rezafungin: a case series [abstract no. O1225]. In: 33rd ECCMID 2023, 15\u201318 April 2023. 2023."},{"issue":"11","key":"2134_CR46","first-page":"1","volume":"8","author":"A Adeel","year":"2021","unstructured":"Adeel A, Qu MD, Siddiqui E, et al. Expanded access use of rezafungin for salvage therapy of invasive candida glabrata infection: a case report. Open Forum Infect Dis. 2021;8(11):1\u20135.","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"2134_CR47","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00570-24","volume":"68","author":"M Castanheira","year":"2024","unstructured":"Castanheira M, Deshpande LM, Rhomberg PR, et al. Recent increase in Candida auris frequency in the SENTRY surveillance program: antifungal activity and genotypic characterization. Antimicrob Agents Chemother. 2024;68(10): e0057024.","journal-title":"Antimicrob Agents Chemother"},{"key":"2134_CR48","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02438-19","author":"M Helleberg","year":"2020","unstructured":"Helleberg M, Jorgensen KM, Hare RK, et al. Rezafungin in vitro activity against contemporary nordic clinical Candida isolates and Candida auris determined by the EUCAST reference method. Antimicrob Agents Chemother. 2020. https:\/\/doi.org\/10.1128\/AAC.02438-19.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02134-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02134-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02134-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T13:31:11Z","timestamp":1741613471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02134-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2134"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02134-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]},"assertion":[{"value":"25 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Simon Fung and Matt Shirley are salaried employees of Adis International Ltd\/Springer Nature, and declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}